Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA [0.03%]
洛拉替尼与奥希替尼一线治疗EGFR突变阳性晚期NSCLC：来自MARIPOSA研究的随机、双盲探索性分析
Se-Hoon Lee,Shun Lu,Hidetoshi Hayashi et al.
Se-Hoon Lee et al.
Introduction: Lazertinib is a CNS-penetrant, third-generation epidermal growth factor (EGFR)-tyrosine kinase inhibitor (TKI) that was selected for combination with amivantamab due to its relatively low rates of wild-type ...
Clinical and Pathologic Phenotyping of mesotheliomas developing in carriers of Germline BAP1 Mutations [0.03%]
布林克BAP1突变携带者胸膜间皮瘤的临床和病理分型研究
Michele Carbone,Michael Minaai,Muaiad Kittaneh et al.
Michele Carbone et al.
Introduction: Mesothelioma is frequent among carriers of inactivating heterozygous germline BAP1 mutations (BAP1+/-). We studied whether the natural history and the pathology of mesotheliomas in BAP1+/- carriers differed ...
Immune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations [0.03%]
BAP1、CDKN2A、MTAP和NF2改变型间皮瘤的免疫组成及免疫治疗效果
Ibiayi Dagogo-Jack,Owen Mitchell,Elizabeth Codd et al.
Ibiayi Dagogo-Jack et al.
Background: First-line mesothelioma treatment paradigms prioritize histology without integrating molecular features. Findings from other thoracic cancers suggest that tumor immune microenvironment (TME) composition and im...
Surgical Outcomes with Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC [0.03%]
新辅助杜瓦鲁单抗联合化疗序贯辅助杜瓦鲁单抗治疗可切除NSCLC的手术结局
Tetsuya Mitsudomi,John V Heymach,Martin Reck et al.
Tetsuya Mitsudomi et al.
Introduction: In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival and pathological complete response (primary endpoints; mod...
Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer [0.03%]
靶向WEE1以克服EGFR突变型肺癌中ARID1A突变驱动的奥希替尼耐药性
Koji Fukuda,Shigeki Nanjo,Shinji Takeuchi et al.
Koji Fukuda et al.
Introduction: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC [0.03%]
德鲁替康联合datopotamab治疗EGFR突变NSCLC患者的汇总分析
Myung-Ju Ahn,Aaron Lisberg,Yasushi Goto et al.
Myung-Ju Ahn et al.
Background: This exploratory analysis assessed datopotamab deruxtecan (Dato-DXd) in pretreated patients with advanced/metastatic NSCLC and EGFR mutations. ...
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma [0.03%]
与早期肺腺癌发病风险相关的致病性和中等 penetrance 宰细胞变异的基因组特征
Hourin Cho,Kouya Shiraishi,Kuniko Sunami et al.
Hourin Cho et al.
Introduction: Up to 54% of all lung adenocarcinoma (LADC) cases in Asian populations occur in never-smoking women, suggesting that the impact of smoking and other environmental factors on the risk of early-onset LADC is m...
A Response to the Letter to the Editor: "POSEIDON's Missing Piece: Unanswered Questions on PFS Data in High-Risk Subgroups" [0.03%]
《致编辑的信：POISEIDON缺失的部分：关于高危亚组PFS数据未决问题的回答》
Solange Peters,Byoung Chul Cho,Melissa L Johnson
Solange Peters
POSEIDON's Missing Piece: Unanswered Questions on Progression-Free Survival Data in High-Risk Subgroups [0.03%]
Poseidon缺失的一环：高危亚组无进展生存期数据未解的问题
Arif Hakan Önder
Arif Hakan Önder
A Response to the Letter to the Editor: "Can We Refine Criteria for the First-Line Treatment for Patients With Advanced ALK-Positive NSCLC?" [0.03%]
针对《致编辑信件：“我们可以改进ALK阳性晚期NSCLC一线治疗选择的评判标准吗？”》的回复
Hui Jing Hoe,Benjamin J Solomon
Hui Jing Hoe